Molecular Mechanisms of Acquiring Resistance to Treatments in Prostate Cancer: Perspectives of Old and New Organelles

Dear Colleagues,

Prostate cancer (PC) is one of the most diagnosed cancers in the world, for which it’s initiation and progression is driven by the androgen–androgen receptor (AR) axis. This axis can be targeted with some androgen deprivation therapies (ADT), which provide an initial benefit. However, 10–20% of cases progress to castration-resistant prostate cancer (CRPC) after ADT. In particular, metastatic CRPC (mCRPC) shows a poor prognosis and remains a significant medical challenge. Mechanisms of acquiring resistance to ADT in prostate cancer include AR overexpression, AR mutations, alterations in AR coactivators, and various signaling pathways. In addition, taxanes are the most active chemotherapy drugs used for mCRPC. mCRPC initially responds well, but it develops resistance as well. It is necessary that the acquisition of resistance to these various treatments is considered from a new perspective. Recently, various organelles such as Golgi apparatus, endoplasmic reticulum, and primary cilia have been shown to acquire resistance to treatments in prostate cancer.

Thus, in order to provide a comprehensive view of the recent advances in the mechanisms of acquiring resistance to treatments in prostate cancer from the perspective of old and new organelles, we invite researchers to submit original research papers and high-quality comprehensive reviews rooted within the molecular oncology research field to this Special Issue.

Prof. Dr. Masatoshi Watanabe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• castration-resistance
• organelle
• endoplasmic reticulum stress
• mitochondria
• Golgi apparatus
• primary cilia
• chemotherapy
• radiation therapy
• immunotherapy
• PARP inhibitor
• chemoresistance
• radio-resistance
• treatment-related neuroendocrine prostate cancer